Researchers from Umeå University have uncovered how a key protein helps cancer cells dodge death, even under chemotherapy and radiation. The work could guide smarter, more targeted cancer treatments.
Cancer therapies like chemotherapy and radiation are designed to push damaged cells over the edge, triggering a built-in self-destruct program so tumors shrink and disappear. But many cancers learn how to dodge this fate, surviving treatment and coming back stronger.
New research from Umeå University in Sweden sheds light on one of the key tricks cancer cells use to stay alive. The study reveals in detail how a protein called Bcl-2 acts as a powerful bodyguard, blocking the cell’s own death machinery and helping tumors resist therapy.
The findings, published in ACS Chemical Biology, focus on apoptosis, a form of programmed cell death. Apoptosis is essential for healthy development, for clearing out old or damaged cells, and for keeping the immune system in balance. When this process breaks down, cells that should die can instead divide uncontrollably and form tumors.
Many standard cancer treatments work by damaging DNA or stressing cells in ways that normally trigger apoptosis. If that self-destruct signal goes through, cancer cells die. But if the signal is blocked, tumors can survive and become resistant to treatment.
At the center of this battle inside the cell are two closely related proteins with opposite roles: Bax and Bcl-2.
Bax is a cell-killing protein. When activated, it travels to the mitochondria, the cell’s energy factories, and forms pores in their outer membranes. This pore formation is a point of no return that launches apoptosis.
Bcl-2, on the other hand, is a cell-protective protein from the same family. It sits on the outer surface of mitochondria and interferes with Bax, preventing it from punching those lethal holes. In nearly half of all human cancers, Bcl-2 is produced at abnormally high levels, tipping the balance toward survival and helping tumors grow and resist therapy.
The Umeå-led team wanted to understand exactly how Bcl-2 manages to keep Bax in check.
To do this, they used advanced neutron-based experiments, working with large-scale research facilities in Sweden, the UK and France. These techniques allowed them to probe how the proteins behave on and within membrane surfaces that mimic the outer layer of mitochondria.
“In our research, we have used advanced neutron experiments to show how Bcl‑2 protects cancer cells by blocking the death‑inducing proteins that are most often activated by therapy,” lead author Gerhard Gröbner, a professor at the Department of Chemistry at Umeå University, said in a news release.
Their experiments showed that Bcl-2 is more efficient at blocking cell death than scientists had realized. Rather than interacting with Bax one at a time, Bcl-2 can capture and bind several Bax molecules simultaneously on the mitochondrial surface.
That ability has major implications. It means cancer cells do not need to produce enormous amounts of Bcl-2 to shut down apoptosis. Even a moderate increase in Bcl-2 levels can be enough to neutralize multiple Bax proteins and keep the cell alive under stress.
The researchers also explored how the composition of the mitochondrial membrane affects this molecular tug-of-war. They focused on cardiolipin, a specialized lipid found in mitochondrial membranes.
Cardiolipin is known to promote apoptosis. It can help Bax insert into the membrane and form the pores that trigger cell death. The team confirmed that cardiolipin supports this pore-forming activity.
However, they also found that cardiolipin’s pro-death influence is not absolute. If Bcl-2 levels are high enough, the protective protein can still prevent apoptosis even in membranes that contain cardiolipin. In other words, a sufficiently strong Bcl-2 presence can override a membrane environment that would otherwise favor cell death.
This detailed picture of how Bcl-2 and Bax interact on mitochondrial membranes helps explain why some tumors are so hard to kill. If Bcl-2 can efficiently mop up multiple Bax molecules, then therapies that rely solely on triggering apoptosis may fail unless they also address this protective shield.
Today, several cancer drugs already aim to target Bcl-2 and related proteins, trying to restore the cell’s ability to undergo apoptosis. The new work adds a more precise understanding of how Bcl-2 operates at the molecular level, which could guide the design of future treatments.
“In the longer term, this type of knowledge could open up new opportunities for cancer treatment, for example by targeting Bcl‑2 and its protective function,” Gröbner added.
The study was a collaboration between researchers at Umeå University, Lund University, the European Spallation Source in Lund, the ISIS Neutron and Muon Source and Diamond Light Source in the UK, and the Institut Laue-Langevin in France.
While the findings are still at the experimental stage and focused on basic cell biology, they point toward a clear goal: weakening cancer’s defenses from the inside. By better understanding how proteins like Bcl-2 help tumors survive, scientists hope to develop therapies that not only attack cancer cells, but also remove their ability to escape the cell’s own death program.
Source: Umeå University